HRP20030388A2 - Use of antiprogestins for the induction of apoptosis in a cell - Google Patents
Use of antiprogestins for the induction of apoptosis in a cell Download PDFInfo
- Publication number
- HRP20030388A2 HRP20030388A2 HR20030388A HRP20030388A HRP20030388A2 HR P20030388 A2 HRP20030388 A2 HR P20030388A2 HR 20030388 A HR20030388 A HR 20030388A HR P20030388 A HRP20030388 A HR P20030388A HR P20030388 A2 HRP20030388 A2 HR P20030388A2
- Authority
- HR
- Croatia
- Prior art keywords
- antiprogestin
- cell
- tumor
- apoptosis
- breast cancer
- Prior art date
Links
- 230000000708 anti-progestin effect Effects 0.000 title claims abstract description 130
- 239000003418 antiprogestin Substances 0.000 title claims abstract description 130
- 230000006882 induction of apoptosis Effects 0.000 title claims description 20
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 60
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 55
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 55
- 210000004027 cell Anatomy 0.000 claims abstract description 45
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 40
- 238000011282 treatment Methods 0.000 claims abstract description 36
- 230000006907 apoptotic process Effects 0.000 claims abstract description 33
- 238000000034 method Methods 0.000 claims abstract description 29
- 201000011510 cancer Diseases 0.000 claims abstract description 17
- 230000018199 S phase Effects 0.000 claims abstract description 14
- 230000001939 inductive effect Effects 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims description 14
- 229940046836 anti-estrogen Drugs 0.000 claims description 13
- 230000001833 anti-estrogenic effect Effects 0.000 claims description 13
- 239000000328 estrogen antagonist Substances 0.000 claims description 13
- 229940079593 drug Drugs 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- 230000011712 cell development Effects 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 6
- 210000004962 mammalian cell Anatomy 0.000 claims description 6
- 210000005260 human cell Anatomy 0.000 claims description 5
- 230000000977 initiatory effect Effects 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 3
- 230000022131 cell cycle Effects 0.000 abstract description 16
- 230000000694 effects Effects 0.000 description 24
- 238000009806 oophorectomy Methods 0.000 description 21
- 230000004614 tumor growth Effects 0.000 description 21
- ZRKWMRDKSOPRRS-UHFFFAOYSA-N N-Methyl-N-nitrosourea Chemical compound O=NN(C)C(N)=O ZRKWMRDKSOPRRS-UHFFFAOYSA-N 0.000 description 18
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 14
- 241000700159 Rattus Species 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 12
- 239000003153 chemical reaction reagent Substances 0.000 description 12
- 230000001419 dependent effect Effects 0.000 description 12
- 229940088597 hormone Drugs 0.000 description 12
- 239000005556 hormone Substances 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 12
- IEXUMDBQLIVNHZ-YOUGDJEHSA-N (8s,11r,13r,14s,17s)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)CCCO)[C@@]2(C)C1 IEXUMDBQLIVNHZ-YOUGDJEHSA-N 0.000 description 11
- 229950011093 onapristone Drugs 0.000 description 11
- 239000000463 material Substances 0.000 description 10
- 108050006400 Cyclin Proteins 0.000 description 9
- 102000009339 Proliferating Cell Nuclear Antigen Human genes 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 7
- 229960005309 estradiol Drugs 0.000 description 7
- 229930182833 estradiol Natural products 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- ARSRBNBHOADGJU-UHFFFAOYSA-N 7,12-dimethyltetraphene Chemical compound C1=CC2=CC=CC=C2C2=C1C(C)=C(C=CC=C1)C1=C2C ARSRBNBHOADGJU-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- 238000009577 estrogen deprivation therapy Methods 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 102000003998 progesterone receptors Human genes 0.000 description 6
- 108090000468 progesterone receptors Proteins 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- VFZRZRDOXPRTSC-UHFFFAOYSA-N DMBA Natural products COC1=CC(OC)=CC(C=O)=C1 VFZRZRDOXPRTSC-UHFFFAOYSA-N 0.000 description 5
- 238000012313 Kruskal-Wallis test Methods 0.000 description 5
- 239000012042 active reagent Substances 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 230000009036 growth inhibition Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229960001603 tamoxifen Drugs 0.000 description 4
- 229920000858 Cyclodextrin Polymers 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 238000011770 Fox Chase SCID mouse Methods 0.000 description 3
- 206010061309 Neoplasm progression Diseases 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000001028 anti-proliverative effect Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000005755 formation reaction Methods 0.000 description 3
- 230000000762 glandular Effects 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 210000004705 lumbosacral region Anatomy 0.000 description 3
- 108010082117 matrigel Proteins 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 229960003248 mifepristone Drugs 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000013223 sprague-dawley female rat Methods 0.000 description 3
- 230000003637 steroidlike Effects 0.000 description 3
- 230000005751 tumor progression Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 2
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 238000012288 TUNEL assay Methods 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 230000025084 cell cycle arrest Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000009261 endocrine therapy Methods 0.000 description 2
- 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 description 2
- -1 for example Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 108091008039 hormone receptors Proteins 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000000583 progesterone congener Substances 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 125000006308 propyl amino group Chemical group 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- AYRABHFHMLXKBT-UHFFFAOYSA-N 2,6-Dimethyl-anthracen Natural products C1=C(C)C=CC2=CC3=CC(C)=CC=C3C=C21 AYRABHFHMLXKBT-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- JEYWNNAZDLFBFF-UHFFFAOYSA-N Nafoxidine Chemical compound C1CC2=CC(OC)=CC=C2C(C=2C=CC(OCCN3CCCC3)=CC=2)=C1C1=CC=CC=C1 JEYWNNAZDLFBFF-UHFFFAOYSA-N 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 206010067572 Oestrogenic effect Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003388 anti-hormonal effect Effects 0.000 description 1
- 230000002513 anti-ovulatory effect Effects 0.000 description 1
- 230000001911 anti-progestational effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003150 biochemical marker Substances 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 238000003235 crystal violet staining Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229940087861 faslodex Drugs 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000012520 frozen sample Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 229950002366 nafoxidine Drugs 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000017095 negative regulation of cell growth Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000000624 ovulatory effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000044 progesterone antagonist Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- 229960004622 raloxifene Drugs 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 102200063830 rs4880 Human genes 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000005477 standard model Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001875 tumorinhibitory effect Effects 0.000 description 1
- 239000006213 vaginal ring Substances 0.000 description 1
- 229940044953 vaginal ring Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24099100P | 2000-10-18 | 2000-10-18 | |
| EP00250342 | 2000-10-18 | ||
| PCT/EP2001/012006 WO2002032432A1 (en) | 2000-10-18 | 2001-10-17 | Use of antiprogestins for the induction of apoptosis in a cell |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20030388A2 true HRP20030388A2 (en) | 2005-04-30 |
Family
ID=26072952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20030388A HRP20030388A2 (en) | 2000-10-18 | 2003-05-14 | Use of antiprogestins for the induction of apoptosis in a cell |
Country Status (29)
| Country | Link |
|---|---|
| EP (1) | EP1326617B9 (uk) |
| JP (1) | JP2004511523A (uk) |
| KR (1) | KR100668024B1 (uk) |
| CN (1) | CN1209111C (uk) |
| AT (1) | ATE334683T1 (uk) |
| AU (2) | AU2361902A (uk) |
| BG (1) | BG107744A (uk) |
| BR (1) | BR0114696A (uk) |
| CA (1) | CA2423020C (uk) |
| CY (1) | CY1105745T1 (uk) |
| CZ (1) | CZ299823B6 (uk) |
| DE (1) | DE60121980T2 (uk) |
| DK (1) | DK1326617T3 (uk) |
| EA (1) | EA010593B1 (uk) |
| EE (1) | EE200300157A (uk) |
| ES (1) | ES2269492T3 (uk) |
| HK (1) | HK1062273A1 (uk) |
| HR (1) | HRP20030388A2 (uk) |
| HU (1) | HUP0301433A3 (uk) |
| IL (2) | IL154976A0 (uk) |
| MX (1) | MXPA03002955A (uk) |
| NO (1) | NO20031741L (uk) |
| NZ (1) | NZ538347A (uk) |
| PL (1) | PL360157A1 (uk) |
| PT (1) | PT1326617E (uk) |
| SI (1) | SI1326617T1 (uk) |
| SK (1) | SK4702003A3 (uk) |
| UA (1) | UA76729C2 (uk) |
| WO (1) | WO2002032432A1 (uk) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY27301A1 (es) * | 2001-05-25 | 2003-02-28 | Schering Ag | Uso y composiciones de antiprogestinas para el tratamiento de enfermedades de la próstata |
| US20040242551A1 (en) * | 2003-05-28 | 2004-12-02 | Schering Ag | Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases |
| WO2008128791A2 (en) * | 2007-04-23 | 2008-10-30 | Bayer Schering Pharma Aktiengesellschaft | Progesterone-receptor antagonist for use in brca-mediated cancer alone or as combination with antiestrogen |
| US20080268041A1 (en) * | 2007-04-23 | 2008-10-30 | Jens Hoffmann | Combination of progesterone-receptor antagonist together with none-steroidal antiestrogen for use in brca mediated diseases |
| JP2010524996A (ja) * | 2007-04-23 | 2010-07-22 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | Ｂｒｃａ媒介性疾患における使用のための、プロゲステロン受容体拮抗薬と、ルテインホルモン放出ホルモン作動薬および拮抗薬との組み合わせ |
| GB0718167D0 (en) | 2007-09-18 | 2007-10-31 | Cancer Rec Tech Ltd | Cancer marker and therapeutic target |
| CN103957920B (zh) * | 2011-10-04 | 2018-04-20 | 因维维斯制药公司 | 用于鉴定和治疗抗黄体制剂敏感性肿瘤的方法和系统 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19706061A1 (de) * | 1997-02-07 | 1998-08-13 | Schering Ag | Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette |
-
2001
- 2001-10-17 PT PT01987669T patent/PT1326617E/pt unknown
- 2001-10-17 SK SK470-2003A patent/SK4702003A3/sk not_active Application Discontinuation
- 2001-10-17 CA CA002423020A patent/CA2423020C/en not_active Expired - Fee Related
- 2001-10-17 AU AU2361902A patent/AU2361902A/xx active Pending
- 2001-10-17 SI SI200130648T patent/SI1326617T1/sl unknown
- 2001-10-17 AU AU2002223619A patent/AU2002223619B2/en not_active Ceased
- 2001-10-17 PL PL01360157A patent/PL360157A1/xx not_active Application Discontinuation
- 2001-10-17 HU HU0301433A patent/HUP0301433A3/hu unknown
- 2001-10-17 EA EA200300479A patent/EA010593B1/ru not_active IP Right Cessation
- 2001-10-17 EP EP01987669A patent/EP1326617B9/en not_active Expired - Lifetime
- 2001-10-17 KR KR1020037005360A patent/KR100668024B1/ko not_active IP Right Cessation
- 2001-10-17 WO PCT/EP2001/012006 patent/WO2002032432A1/en active IP Right Grant
- 2001-10-17 DK DK01987669T patent/DK1326617T3/da active
- 2001-10-17 CN CNB018175694A patent/CN1209111C/zh not_active Expired - Fee Related
- 2001-10-17 DE DE60121980T patent/DE60121980T2/de not_active Expired - Fee Related
- 2001-10-17 BR BR0114696-3A patent/BR0114696A/pt not_active Application Discontinuation
- 2001-10-17 CZ CZ20031073A patent/CZ299823B6/cs not_active IP Right Cessation
- 2001-10-17 MX MXPA03002955A patent/MXPA03002955A/es active IP Right Grant
- 2001-10-17 JP JP2002535670A patent/JP2004511523A/ja active Pending
- 2001-10-17 ES ES01987669T patent/ES2269492T3/es not_active Expired - Lifetime
- 2001-10-17 EE EEP200300157A patent/EE200300157A/xx unknown
- 2001-10-17 NZ NZ538347A patent/NZ538347A/en unknown
- 2001-10-17 UA UA2003054311A patent/UA76729C2/uk unknown
- 2001-10-17 IL IL15497601A patent/IL154976A0/xx active IP Right Grant
- 2001-10-17 AT AT01987669T patent/ATE334683T1/de not_active IP Right Cessation
-
2003
- 2003-03-18 IL IL154976A patent/IL154976A/en not_active IP Right Cessation
- 2003-04-15 NO NO20031741A patent/NO20031741L/no not_active Application Discontinuation
- 2003-04-18 BG BG107744A patent/BG107744A/bg unknown
- 2003-05-14 HR HR20030388A patent/HRP20030388A2/hr not_active Application Discontinuation
-
2004
- 2004-07-20 HK HK04105309A patent/HK1062273A1/xx not_active IP Right Cessation
-
2006
- 2006-11-01 CY CY20061101564T patent/CY1105745T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60216630T2 (de) | Verwendung von östrogen in kombination mit progestogen für die hormonsubstitutiionstherapie | |
| US8048869B2 (en) | Pharmaceutical composition for use in hormone replacement therapy | |
| US8735381B2 (en) | Progesterone antagonists such as CDB-4124 in the treatment of endometriosis, uterine fibroids, dysmenorrhea, breast cancer, etc | |
| HU221589B (hu) | Emlő- és méhrák kezelésére alkalmas kombinációs gyógyszerkészítmény és eljárás előállítására | |
| JP2010077158A (ja) | ホルモン−依存性疾病の予防及び処理のための抗黄体ホルモンの使用 | |
| Robbins et al. | Mifepristone: clinical pharmacology | |
| KR20090067198A (ko) | 자궁내막 증식을 억제하는 조성물과 방법 | |
| HRP20030388A2 (en) | Use of antiprogestins for the induction of apoptosis in a cell | |
| Yano et al. | Inhibition of growth of MCF-7 MIII human breast carcinoma in nude mice by treatment with agonists or antagonists of LH-RH | |
| US20040072811A1 (en) | Use of antiprogestins for the induction of apoptosis in a cell | |
| AU2002223619A1 (en) | Use of antiprogestins for the induction of apoptosis in a cell | |
| KR20030044006A (ko) | 종양 세포의 성장 인자 의존성의 저해 | |
| JP4263264B2 (ja) | 解離したエストロゲン活性を有する薬剤を製造するための１１位置換ステロイド化合物の用途 | |
| TWI306403B (en) | Use of antiprogestings for the induction of apoptosis in a cell | |
| DiPasquale et al. | Action of an estradiol-17β antagonist in intact, ovariectomized, hypophysectomized and hypophysectomized-ovariectomized rats | |
| UA75615C2 (en) | Use of antiprogestins for preventing or treating hormone-dependent diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
| PNAN | Change of the applicant name, address/residence |
Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, DE |
|
| ODBI | Application refused |